Quarterly Financial Results
Granules India Reports Strong Q1 FY27 Performance with 22% Revenue Growth and 60% Jump in Profit
NSE
GRANULES
BSE
532482
- Granules India Limited delivered a strong Q1 FY27 performance, with revenue from operations increasing 22% YoY to ₹1,476.8 crore.
- Operating profitability remained robust as EBITDA rose 37% YoY to ₹338.9 crore, while Profit After Tax (PAT) surged 60% YoY to ₹180 crore.
- The quarter also reflected continued balance sheet improvement, with net debt reducing to ₹101.2 crore and ROCE improving to 18%, supported by growth across finished dosages and a diversified product portfolio.Â
PRICE-SENSITIVE TRIGGER
Event: Granules India announced its unaudited consolidated financial results for the quarter ended 30 June 2026 (Q1 FY27).
Type: Quarterly Financial Results
Impact: Positive
Immediate Effect: The company reported healthy revenue growth, significant expansion in profitability, stronger returns on capital, and continued reduction in leverage, indicating improved operational performance and financial strength.Â
Metrics:
Key Financial Metrics:
- Revenue from Operations: ₹1,476.8 crore (+22% YoY)
- EBITDA: ₹338.9 crore (+37% YoY)
- EBITDA Margin: 23% (vs 20% in Q1 FY26)
- Profit Before Tax (Before Exceptional Items): ₹240.4 crore (+41% YoY)
- Profit After Tax (PAT): ₹180.0 crore (+60% YoY)
- PAT Margin: 12% (vs 9% in Q1 FY26)
- Return on Capital Employed (ROCE): 18.0% (vs 17.6% in FY26)
- Net Debt: ₹101.2 crore
- Net Debt Reduction: ₹846.7 crore YoY
- Net Debt to EBITDA:Â 0.07x
Revenue Mix:
- Finished Dosages (FD):Â 74%
- Active Pharmaceutical Ingredients (API):Â 13%
- Pharmaceutical Formulation Intermediates (PFI):Â 9%
- Peptides CDMO:Â 4%
Geographic Revenue Mix:
- North America:Â 72%
- Europe:Â 16%
Highlight:
- Granules India delivered broad-based earnings growth, with PAT rising 60% YoY and EBITDA margin expanding to 23%, while reducing net debt to just ₹101.2 crore.
What Happened ?
Granules India reported strong financial performance in Q1 FY27, driven by healthy revenue growth and improved profitability across its pharmaceutical business.
The company continued to strengthen its balance sheet through significant debt reduction while maintaining investments in complex generics, peptides, digitalization, operational excellence, sustainability and research & development. Management also reiterated its focus on portfolio transformation, regulatory excellence and geographical diversification to drive long-term growth.Â
key details
Business & Operational Updates:
- Revenue from operations increased 22% YoY to ₹1,476.8 crore.
- EBITDA grew 37% YoY to ₹338.9 crore, with EBITDA margin improving to 23%.
- Profit Before Tax (before exceptional items) increased 41% YoY.
- Profit After Tax jumped 60% YoY, reflecting improved operating efficiency and profitability.
- Finished Dosages remained the company’s largest business, contributing 74% of total revenue.
- North America continued as the largest market, contributing 72% of revenue, while Europe increased its share to 16%.
- ROCE improved to 18.0%, indicating better capital efficiency.
- Net debt reduced by ₹846.7 crore year-on-year to ₹101.2 crore, resulting in a very low Net Debt/EBITDA ratio of 0.07x.
- The company continues to invest in:
- Complex generic products
- Peptides CDMO
- Digital transformation
- Operational excellence
- Sustainability initiatives
- Regulatory and quality systems
- Talent development
Note:
- Despite strong year-on-year growth, quarterly comparisons show EBITDA declined 4% QoQ and PAT declined 11% QoQ, primarily due to the exceptionally strong preceding quarter. However, overall profitability remained significantly higher than the corresponding quarter of the previous year.Â
Risk Analysis
Summary:
- Granules India continues to demonstrate improving profitability and financial discipline. However, management expects external cost pressures and supply chain volatility to remain key challenges over the next few quarters.
Key Risks:
- Raw material cost inflation and supply chain volatility could impact margins.
- Heavy dependence on North America (72% of revenue) exposes the company to regulatory and pricing risks.
- Continued investments in R&D and portfolio transformation may affect short-term margins.
- Pharmaceutical businesses remain exposed to regulatory inspections and compliance requirements.
- Future growth depends on successful commercialization of complex generics and differentiated products.Â
Worst Case:
- Persistent supply chain disruptions, pricing pressure in regulated markets, or delays in scaling complex product launches could moderate earnings growth despite a stronger balance sheet.
Risk Level: Medium
Company Commentary
- Chairman & Managing Director Dr. Krishna Prasad Chigurupati stated that Q1 FY27 reflects the benefits of the strategic initiatives undertaken during FY26.
- Management remains focused on:
- Regulatory and quality excellence.
- Portfolio transformation toward complex and differentiated products.
- Geographic and customer diversification.
- Scaling new growth engines.
- The company will continue investing in R&D, digitalization, operational excellence, sustainability and talent development to support long-term value creation.
- Despite external cost pressures and supply chain volatility, management expressed confidence in delivering sustainable long-term growth supported by a stronger organization and balanced portfolio.Â
Official Exchange Filing: Granules India Limited
